Health Breast Cancer S New Era
Stopping such a big and important study is exceptional, but so were the results: letrozole reduced the risk of recurrence among older women by 43 percent. (Most of the 211,000 women diagnosed with breast cancer in the United States each year are postmenopausal.) Goss and his colleagues in the United States and Europe were testing the drug as a follow-up treatment. The women in the letrozole study had recently completed (after surgery) the standard five-year course of tamoxifen, a powerful and widely used drug that eventually loses its effectiveness as, researchers believe, tumors become resistant to it....